Leti and EPFL Expand R&D Partnership with Monthly Seminars on Micro- and Nanotechnology Topics
News May 07, 2009
Leti and Ecole Polytechnique Fédérale de Lausanne (EPFL) have begun a monthly seminar series for students and professionals to discuss technical issues facing micro- and nanotechnology researchers.
Designed to supplement their recent R&D agreement, the series will focus on such topics as fabrication and design of nanometer-scale regular circuits, 3D integration, brain-computer interface and beyond CMOS. The collaboration is designed to attract students and post-doctorate researchers for “common subjects” at both organizations.
The next two seminars are:
• "Design Technologies for 3D Integration," Dr. Vasileios Pavlidis, May 29 at Leti
• "Lab-on-Chip for Cancer Diagnosis," Dr. Pierre Grangeat, July 2 at EPFL
“Leti and EPFL have many complementary programs and strengths that can benefit both organizations,” said Marie-Noëlle Séméria, Leti’s vice president for strategy and international business development. “Leti’s research projects and state-of-the-art platforms offer unique R&D opportunities for EPFL researchers and post-doctorate engineers. EPFL has an international reputation as a leading engineering school that also is focused on creating innovation, technology transfer and working with start-ups. EPFL is a strategic partner for Leti”.
“In addition to research programs that are aimed at bringing new micro- and nanotechnology capabilities to the market, EPFL has a long tradition of partnering with companies and research centers,” said Giovanni De Michelli, director of the Institute of Electrical Engineering at EPFL. “This collaboration with Leti offers EPFL engineers and researchers the opportunities to continue their work on innovation and technology transfer with established, international companies.”
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare DiseasesNews
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition.READ MORE
Rapid Test Helps with Administering the "Correct" DrugNews
In just three hours, a new rapid test will give information on which available antibiotic is still effective in a concrete case.READ MORE
Nanotechnology Detects Molecular Biomarker for OsteoarthritisNews
For the first time, scientists have been able to measure a specific molecule indicative of osteoarthritis and a number of other inflammatory diseases using a newly developed technology. This preclinical study used a solid-state nanopore sensor as a tool for the analysis of hyaluronic acid.READ MORE